Ensysce Biosciences, Inc. ENSC
0.41
0.01
2.50%
as of 25 Sep
- Market cap
- $7.8M
- P/E
- 0.0×
Follow ENSC
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/S ratio |
0.46 | 1.09 | 1.13 | 0.68 | 26.83 | 0.00 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/Operating CF |
(1.54) | (7.44) | (1.40) | (0.52) | (25.15) | (369.00) | — | — | — |
P/B ratio |
0.82 | 1.68 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Price to Tangible BV |
0.82 | 1.68 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Sales |
(0.27) | 0.53 | 0.89 | 1.18 | 28.19 | 0.00 | — | — | — |
EV/EBITDA |
0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
0.17 | (0.37) | (0.18) | (0.17) | (12.08) | (158.93) | — | — | — |
EV/FCF |
0.17 | (0.37) | (0.18) | (0.17) | (12.08) | (158.93) | — | — | — |
Quick Ratio |
1.04 | 1.64 | 0.37 | 0.36 | 0.77 | 0.03 | 0.43 | 4.18 | 13.38 |
Current Ratio |
1.59 | 2.42 | 0.69 | 0.56 | 0.95 | 0.05 | 0.43 | 4.38 | 14.77 |
Net Debt/EBITDA |
0.42 | 0.63 | 0.11 | (0.05) | (0.24) | (0.79) | 0.15 | 1.73 | 14.25 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 74.88% | 103.86% | 415.46% | 0.29% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | (1.09) | (2.09) | (0.22) | 0.11 | 0.00 | 0.00 |
Asset Turnover |
0.78 | 1.25 | 0.52 | 0.23 | 0.42 | 0.04 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.77 | 0.94 | 1.01 | 0.71 | 0.28 | (21.96) | 1.34 | (0.58) | 8.07 |
Capex/Depreciation |
(19.02) | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (324.86%) | (585.44%) | 454.02% | 411.65% | 403.43% | (6.85%) | (21.35%) | 42.44% | (0.62%) | |
| (155.95%) | (192.34%) | (247.31%) | (224.96%) | (356.45%) | 0.06% | (0.53%) | 1.04% | (0.02%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (46.18%) | (17.94%) | 0.00% |
Return on Tangible Assets |
(363.56%) | (254.57%) | 1,017.72% | 602.29% | 3,648.75% | (0.85%) | 67.92% | 143.56% | (1.45%) |
Average Days of Receivables |
30.28 | 8.69 | 15.97 | 40.04 | 45.66 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
204.81% | 138.57% | 340.17% | 786.08% | 132.82% | 111.66% | — | — | — |
Selling, General and Administrative Expense of Revenue |
97.32% | 90.61% | 240.36% | 273.82% | 529.89% | 29.38% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
3.50% | 2.12% | 39.42% | 42.47% | 3.45% | 4.55% | — | — | — |
Graham Net Nets |
1.14 | 0.55 | (0.43) | (2.67) | (0.09) | (0.03) | — | — | — |
Graham Number |
0.00 | 0.00 | 85.80 | 4,147.55 | 12,277.64 | 1,118.22 | — | — | — |
Earnings Yield |
(458.70%) | (164.56%) | (455.63%) | (1,581.09%) | (27.18%) | (0.08%) | — | — | — |
Free Cash Flow Yield |
(331.84%) | (132.05%) | (428.77%) | (1,035.15%) | (8.70%) | (0.63%) | — | — | — |
Revenue per Share |
1.98 | 7.46 | 14.77 | 210.28 | 630.57 | 893.45 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(3.05) | (10.75) | (71.39) | (1,490.62) | (1,471.82) | (283.48) | (838.12) | (728.41) | (0.20) |
Capex per Share |
(0.05) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(3.10) | (10.75) | (71.39) | (1,490.62) | (1,471.82) | (283.48) | (838.12) | (728.41) | (0.20) |
Cash per Share |
1.69 | 5.02 | 7.44 | 262.31 | 2,190.13 | 44.14 | 624.24 | 975.53 | 1.66 |
Shareholders Equity per Share |
1.13 | 4.84 | (4.31) | (335.81) | (1,456.80) | (1,513.27) | 2,941.18 | 2,941.18 | 3.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.13 | 4.84 | (4.31) | (335.81) | (1,456.80) | (1,513.27) | 2,941.18 | 2,941.18 | 3.97 |
Free Cash Flow |
(7.93) | (7.50) | (10.78) | (17.89) | (8.24) | (1.25) | (1.42) | (1.24) | (0.25) |
Working Capital |
2.67 | 3.14 | (1.04) | (4.16) | (0.82) | (6.66) | (1.57) | 1.48 | 2.15 |
Capital Expenditures |
(0.12) | — | — | — | — | — | — | — | — |
Net Current Asset Value |
2.67 | 3.13 | (1.07) | (4.62) | (8.91) | (6.66) | (190.31) | (197.92) | (195.12) |
EV/EBIT |
0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Net Profit Margin |
(200.83%) | (153.31%) | (476.40%) | (994.12%) | (846.37%) | 1.44% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.05 | 0.00 | 0.00 | — | 0.00 | 1.00 | — | — | — |
Cash ROIC |
(110.22%) | (109.02%) | (2,282.45%) | (507.49%) | (38.96%) | 24.94% | (21.50%) | (18.60%) | (3.55%) |
Accounts Receivable Turnover |
18.61 | 47.00 | 11.92 | 7.02 | 12.17 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.27 | 0.11 | 0.19 | 0.36 | 0.29 | — | 0.15 | 0.15 | — |
Average Payables |
2.31 | 1.65 | 2.44 | 1.62 | 1.01 | 2.25 | 1.60 | 0.27 | 0.27 |
Average Assets |
6.52 | 4.15 | 4.30 | 11.15 | 8.38 | 98.43 | 200.67 | 203.63 | 203.63 |
Average Common Equity |
3.13 | 1.36 | (2.34) | (6.09) | (7.41) | (0.83) | 5.00 | 5.00 | 5.00 |
Columns are period end dates